

ROCKWELL MEDICAL TECHNOLOGIES INC  
Form 8-K  
July 28, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

Current Report  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 26, 2011

**Rockwell Medical Technologies, Inc.**  
(Exact name of registrant as specified in its charter)

**Michigan**  
(State or other jurisdiction  
of incorporation)

**000-23661**  
(Commission file number)

**38-3317208**  
(I.R.S. Employer  
Identification No.)

**30142 Wixom Road, Wixom, Michigan**  
(Address of principal executive offices)

**48393**  
(Zip Code)

**(248) 960-9009**  
(Registrant's telephone number, including area code)

**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events.**

On July 26, 2011, Rockwell Medical Technologies, Inc. (the "Company") issued a press release announcing its acquisition of an Abbreviated New Drug Application for injectable, active Vitamin-D (Calcitriol) for End Stage Renal Disease patients undergoing hemodialysis. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

Exhibit 99.1

Press Release, dated July 26,  
2011

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**Rockwell Medical Technologies, Inc.**

Date: July 27, 2011

By: /s/ THOMAS E. KLEMA  
Thomas E. Klema  
Its: Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit 99.1 Press Release, dated July 26,  
2011